Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9178009 | 0.85 | KMT2A (1.00) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL31717037 | 0.80 | KMT2A (0.64) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL27902884 | 0.79 | GAA (0.68) | LMNAMAPTRAB9APOLB | |
| SCHEMBL31338440 | 0.79 | KMT2A (0.76) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL28957724 | 0.78 | KMT2A (0.80) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL31716910 | 0.78 | KMT2A (0.80) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL4099549 | 0.78 | KMT2A (0.74) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL16144822 | 0.77 | KMT2A (0.73) | KMT2ATNKS2KDM4ELMNAMAPT | |
| SCHEMBL28206029 | 0.77 | PDE10A (0.67) | KMT2ATNKS2LMNASMN1; SMN2PDE10A | |
| SCHEMBL2260560 | 0.77 | TNKS2 (0.70) | KMT2ATNKS2KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | VANDERBILT UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
| WO-2018212774-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | NRAS, KRAS, MAVS | KMT2A 3348/4885TNKS2 1341/4885KDM4E 3713/4885 |
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | NRAS, KRAS, MAVS | KMT2A 3348/4885TNKS2 1341/4885KDM4E 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.